Intellia Therapeutics appoints CFO [Seeking Alpha]
![Seeking Alpha](../../../Content/images/providers/Seeking Alpha.png)
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Seeking Alpha
NTLA shares were trading pre-market. Dulac will succeed Glenn Goddard, who is stepping down from the role on June 30. Dulac most recently served as CFO of Fate Therapeutics. Recommended For You More Trending News About NTLA Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics, Inc. (NASDAQ: FATE) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $6.00 price target on the stock, up previously from $4.00.MarketBeat
- FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the FirmPR Newswire
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Fate Therapeutics to Present at 2024 Jefferies Global Healthcare ConferenceGlobeNewswire
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.00. They now have a "neutral" rating on the stock.MarketBeat
FATE
Earnings
- 5/9/24 - Beat
FATE
Sec Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- FATE's page on the SEC website